CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Ronald Grunstein

OPENALEX: A5021013704↗ORCID: 0000-0001-6682-5812↗

Affiliations

Organizations

Harry Perkins Institute of Medical Researchauthorship · AU Macquarie Universityauthorship · AU Royal Prince Alfred Hospitalauthorship · AU The University of Sydneyauthorship · AU Woolcock Institute of Medical Researchauthorship · AU

Public evidence

3 connected articles

Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.2024 · Europe PMC Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial.2023 · PubMed Central Open Access Orally administered cannabidiol does not produce false-positive tests for Δ<sup>9</sup> -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.2022 · Europe PMC

Registered research

Connected studies

A Randomised, Double-blind, Placebo-controlled, Single-dose, Crossover, Pilot Study Investigating the Effects of Cannabinol (CBN) 30 mg and 300 mg on Sleep Architecture and Next-day Function in Insomnia Disordernct05344170

Matched by exact identifiers only. Profile data: ORCID. Last retrieved 23/08/2026.

Ronald Grunstein - Medical Cannabis Research Engine